Klinikum Frankfurt (Oder) GmbH — Clinical Trial Site

8 Registered trials

4 Currently recruiting

Organisation

Klinikum Frankfurt (Oder) GmbH

Location

Frankfurt (Oder), Germany

Identifier

ORG-100024626

Address

Muellroser Chaussee 7, Markendorf, 15236, Germany

Departments

-
Department for Oncology, Haematology, Pneumology
Klinik für Psychiatrie und Psychotherapie
Klinikum Frankfurt(Oder) GmbH, Medizinische Klinik I
Medizinische Klinik I
Medizinische Klinik I: Haematologie und Onkologie

Clinical trials at this site (8)

Search interface

A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressi… Recruiting

2022-502783-21-00 B-Cell Non-Hodgkin's Lymphoma 5 2024-02-20
A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting

2022-502660-20-00 Follicular lymphoma 5 2024-01-23
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended

2024-515375-35-00 Untreated patients with higher risk MDS and oligoblasti 4 2019-08-26
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Chronic Lymphocytic Leukemia (CLL) 5 2014-12-18